Skip to main content

Table 3 A Brief Summary of Responses to EGFR-TKI Treatment in cavitary and noncavitary adenocarcinoma patients with EGFR mutations

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Characteristic Cavity
N = 15
Noncavity
N = 261
P
Response, no. (%)
 CR 0 (0.0) 0 (0.0)  
 PR 8 (53.3) 154 (59.0)  
 SD 6 (40.0) 86 (33.0)  
 PD 1 (6.7) 21 (8.0)  
mPFS (95%CI), mo
 Overall cohort 6.5 (5.3–7.7) 11.0 (9.3–12.7) 0.006
 Exon 19 deletion 9.7 (2.1–17.3) 10.4 (9.0–11.8) 0.483
 L858R mutation 4.2 (2.5–5.9) 11.0 (7.6–14.4) < 0.001
ORR, %
 Overall cohort 53.3 59.0 0.664
 Exon 19 deletion 55.6 61.1 0.737
 L858R mutation 50.0 54.8 1.000
DCR, %
 Overall cohort 93.3 92.0 1.000
 Exon 19 deletion 100.0 90.7 1.000
 L858R mutation 83.3 92.7 0.387
  1. Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, CR complete response, PR partial response, SD stable disease, PD progressive disease, mPFS median progression-free survival, ORR objective response rate, DCR disease control rate